The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension

Current guidelines for the treatment of patients with idiopathic pulmonary arterial hypertension (IPAH) recommend basing therapeutic decision-making on haemodynamic, functional and biochemical variables. Most of these parameters have been evaluated as risk predictors at the time of diagnosis. The ai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal 2012-03, Vol.39 (3), p.589-596
Hauptverfasser: NICKEL, N, GOLPON, H, GREER, M, KNUDSEN, L, OLSSON, K, WESTERKAMP, V, WELTE, T, HOEPER, M. M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 596
container_issue 3
container_start_page 589
container_title The European respiratory journal
container_volume 39
creator NICKEL, N
GOLPON, H
GREER, M
KNUDSEN, L
OLSSON, K
WESTERKAMP, V
WELTE, T
HOEPER, M. M
description Current guidelines for the treatment of patients with idiopathic pulmonary arterial hypertension (IPAH) recommend basing therapeutic decision-making on haemodynamic, functional and biochemical variables. Most of these parameters have been evaluated as risk predictors at the time of diagnosis. The aim of the present study was to assess the prognostic impact of changes in these parameters after initiation of targeted therapy. A cohort of 109 patients with IPAH who had undergone haemodynamic, functional and biochemical assessments at baseline and 3-12 months after initiation of pulmonary arterial hypertension (PAH)-targeted therapy, were followed for a median 38 months in order to determine predictors of mortality at baseline and during the course of their disease. Within the observation period, 53 (48.6%) patients died and four (3.7%) underwent lung transplantation. Kaplan-Meier estimates for transplantation-free survival were 92%, 67%, and 51% at 1, 3, and 5 yrs, respectively. Among baseline variables, 6-min walk distance, right atrial pressure, cardiac index, mixed-venous oxygen saturation (S(v,O(2))) and N-terminal-pro brain natriuretic peptide (NT-proBNP) were independent predictors of survival. During follow-up, changes in World Health Organization functional class, cardiac index, S(v,O(2)) and NT-proBNP proved significant predictors of outcome. When assigned to prognostic groups, improvements as well as deteriorations in these parameters after initiation of PAH-targeted therapy had a strong impact on survival. Measurements obtained at follow-up had a higher predictive value than variables obtained at baseline. Changes in established predictors of outcome during the course of the disease provide important prognostic information in patients with IPAH.
doi_str_mv 10.1183/09031936.00092311
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_926153195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>926153195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-44e8e37a49808afa8e433ab974cff3920e1bb78d0a4f846078f1c05e9e7f31fe3</originalsourceid><addsrcrecordid>eNpFkU1PwzAMhiMEYmPwA7igXBCnjmRu1-SIJr6kSVzGucoyh2Vqm1K3mvbvydgGp1jJ81r2E8ZupRhLqeBRaAFSw3QshNATkPKMDSVonYAQcM6G-_dkDwzYFdFGCDlNQV6ywUQqlYGeDNlmsUbetOGrDtR5y33VGNvx4LgLZRm2Sd9wQ4REFdYdcV_zxnT-t976bs39yod4s47Zpi-rUJt2x03bYetNyde7BmNdkw_1NbtwpiS8OZ4j9vnyvJi9JfOP1_fZ0zyxkEOXpCkqhNykWgllnFGYApilzlPrXJxZoFwuc7USJnUqnYpcOWlFhhpzB9IhjNjDoW9c67tH6orKk8WyNDWGngo9mcosessiKQ-kbQNRi65oWl_FBQopir3h4mS4OBmOmbtj935Z4eovcVIagfsjYMia0rWmtp7-uSzL4x_l8AOnFYVu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>926153195</pqid></control><display><type>article</type><title>The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>NICKEL, N ; GOLPON, H ; GREER, M ; KNUDSEN, L ; OLSSON, K ; WESTERKAMP, V ; WELTE, T ; HOEPER, M. M</creator><creatorcontrib>NICKEL, N ; GOLPON, H ; GREER, M ; KNUDSEN, L ; OLSSON, K ; WESTERKAMP, V ; WELTE, T ; HOEPER, M. M</creatorcontrib><description>Current guidelines for the treatment of patients with idiopathic pulmonary arterial hypertension (IPAH) recommend basing therapeutic decision-making on haemodynamic, functional and biochemical variables. Most of these parameters have been evaluated as risk predictors at the time of diagnosis. The aim of the present study was to assess the prognostic impact of changes in these parameters after initiation of targeted therapy. A cohort of 109 patients with IPAH who had undergone haemodynamic, functional and biochemical assessments at baseline and 3-12 months after initiation of pulmonary arterial hypertension (PAH)-targeted therapy, were followed for a median 38 months in order to determine predictors of mortality at baseline and during the course of their disease. Within the observation period, 53 (48.6%) patients died and four (3.7%) underwent lung transplantation. Kaplan-Meier estimates for transplantation-free survival were 92%, 67%, and 51% at 1, 3, and 5 yrs, respectively. Among baseline variables, 6-min walk distance, right atrial pressure, cardiac index, mixed-venous oxygen saturation (S(v,O(2))) and N-terminal-pro brain natriuretic peptide (NT-proBNP) were independent predictors of survival. During follow-up, changes in World Health Organization functional class, cardiac index, S(v,O(2)) and NT-proBNP proved significant predictors of outcome. When assigned to prognostic groups, improvements as well as deteriorations in these parameters after initiation of PAH-targeted therapy had a strong impact on survival. Measurements obtained at follow-up had a higher predictive value than variables obtained at baseline. Changes in established predictors of outcome during the course of the disease provide important prognostic information in patients with IPAH.</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/09031936.00092311</identifier><identifier>PMID: 21885392</identifier><language>eng</language><publisher>Leeds: Maney</publisher><subject>Adult ; Aged ; Atrial Function, Right - physiology ; Biological and medical sciences ; Cohort Studies ; Endothelin Receptor Antagonists ; Epoprostenol - analogs &amp; derivatives ; Epoprostenol - therapeutic use ; Exercise Test ; Familial Primary Pulmonary Hypertension ; Female ; Follow-Up Studies ; Humans ; Hypertension, Pulmonary - drug therapy ; Hypertension, Pulmonary - mortality ; Hypertension, Pulmonary - surgery ; Lung Transplantation ; Male ; Medical sciences ; Middle Aged ; Natriuretic Peptide, Brain - blood ; Oxygen - blood ; Peptide Fragments - blood ; Phosphodiesterase 5 Inhibitors - therapeutic use ; Pneumology ; Prognosis ; Prostaglandins - therapeutic use ; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>The European respiratory journal, 2012-03, Vol.39 (3), p.589-596</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-44e8e37a49808afa8e433ab974cff3920e1bb78d0a4f846078f1c05e9e7f31fe3</citedby><cites>FETCH-LOGICAL-c373t-44e8e37a49808afa8e433ab974cff3920e1bb78d0a4f846078f1c05e9e7f31fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25571397$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21885392$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NICKEL, N</creatorcontrib><creatorcontrib>GOLPON, H</creatorcontrib><creatorcontrib>GREER, M</creatorcontrib><creatorcontrib>KNUDSEN, L</creatorcontrib><creatorcontrib>OLSSON, K</creatorcontrib><creatorcontrib>WESTERKAMP, V</creatorcontrib><creatorcontrib>WELTE, T</creatorcontrib><creatorcontrib>HOEPER, M. M</creatorcontrib><title>The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>Current guidelines for the treatment of patients with idiopathic pulmonary arterial hypertension (IPAH) recommend basing therapeutic decision-making on haemodynamic, functional and biochemical variables. Most of these parameters have been evaluated as risk predictors at the time of diagnosis. The aim of the present study was to assess the prognostic impact of changes in these parameters after initiation of targeted therapy. A cohort of 109 patients with IPAH who had undergone haemodynamic, functional and biochemical assessments at baseline and 3-12 months after initiation of pulmonary arterial hypertension (PAH)-targeted therapy, were followed for a median 38 months in order to determine predictors of mortality at baseline and during the course of their disease. Within the observation period, 53 (48.6%) patients died and four (3.7%) underwent lung transplantation. Kaplan-Meier estimates for transplantation-free survival were 92%, 67%, and 51% at 1, 3, and 5 yrs, respectively. Among baseline variables, 6-min walk distance, right atrial pressure, cardiac index, mixed-venous oxygen saturation (S(v,O(2))) and N-terminal-pro brain natriuretic peptide (NT-proBNP) were independent predictors of survival. During follow-up, changes in World Health Organization functional class, cardiac index, S(v,O(2)) and NT-proBNP proved significant predictors of outcome. When assigned to prognostic groups, improvements as well as deteriorations in these parameters after initiation of PAH-targeted therapy had a strong impact on survival. Measurements obtained at follow-up had a higher predictive value than variables obtained at baseline. Changes in established predictors of outcome during the course of the disease provide important prognostic information in patients with IPAH.</description><subject>Adult</subject><subject>Aged</subject><subject>Atrial Function, Right - physiology</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Endothelin Receptor Antagonists</subject><subject>Epoprostenol - analogs &amp; derivatives</subject><subject>Epoprostenol - therapeutic use</subject><subject>Exercise Test</subject><subject>Familial Primary Pulmonary Hypertension</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Hypertension, Pulmonary - mortality</subject><subject>Hypertension, Pulmonary - surgery</subject><subject>Lung Transplantation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>Oxygen - blood</subject><subject>Peptide Fragments - blood</subject><subject>Phosphodiesterase 5 Inhibitors - therapeutic use</subject><subject>Pneumology</subject><subject>Prognosis</subject><subject>Prostaglandins - therapeutic use</subject><subject>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1PwzAMhiMEYmPwA7igXBCnjmRu1-SIJr6kSVzGucoyh2Vqm1K3mvbvydgGp1jJ81r2E8ZupRhLqeBRaAFSw3QshNATkPKMDSVonYAQcM6G-_dkDwzYFdFGCDlNQV6ywUQqlYGeDNlmsUbetOGrDtR5y33VGNvx4LgLZRm2Sd9wQ4REFdYdcV_zxnT-t976bs39yod4s47Zpi-rUJt2x03bYetNyde7BmNdkw_1NbtwpiS8OZ4j9vnyvJi9JfOP1_fZ0zyxkEOXpCkqhNykWgllnFGYApilzlPrXJxZoFwuc7USJnUqnYpcOWlFhhpzB9IhjNjDoW9c67tH6orKk8WyNDWGngo9mcosessiKQ-kbQNRi65oWl_FBQopir3h4mS4OBmOmbtj935Z4eovcVIagfsjYMia0rWmtp7-uSzL4x_l8AOnFYVu</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>NICKEL, N</creator><creator>GOLPON, H</creator><creator>GREER, M</creator><creator>KNUDSEN, L</creator><creator>OLSSON, K</creator><creator>WESTERKAMP, V</creator><creator>WELTE, T</creator><creator>HOEPER, M. M</creator><general>Maney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120301</creationdate><title>The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension</title><author>NICKEL, N ; GOLPON, H ; GREER, M ; KNUDSEN, L ; OLSSON, K ; WESTERKAMP, V ; WELTE, T ; HOEPER, M. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-44e8e37a49808afa8e433ab974cff3920e1bb78d0a4f846078f1c05e9e7f31fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Atrial Function, Right - physiology</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Endothelin Receptor Antagonists</topic><topic>Epoprostenol - analogs &amp; derivatives</topic><topic>Epoprostenol - therapeutic use</topic><topic>Exercise Test</topic><topic>Familial Primary Pulmonary Hypertension</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Hypertension, Pulmonary - mortality</topic><topic>Hypertension, Pulmonary - surgery</topic><topic>Lung Transplantation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>Oxygen - blood</topic><topic>Peptide Fragments - blood</topic><topic>Phosphodiesterase 5 Inhibitors - therapeutic use</topic><topic>Pneumology</topic><topic>Prognosis</topic><topic>Prostaglandins - therapeutic use</topic><topic>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NICKEL, N</creatorcontrib><creatorcontrib>GOLPON, H</creatorcontrib><creatorcontrib>GREER, M</creatorcontrib><creatorcontrib>KNUDSEN, L</creatorcontrib><creatorcontrib>OLSSON, K</creatorcontrib><creatorcontrib>WESTERKAMP, V</creatorcontrib><creatorcontrib>WELTE, T</creatorcontrib><creatorcontrib>HOEPER, M. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NICKEL, N</au><au>GOLPON, H</au><au>GREER, M</au><au>KNUDSEN, L</au><au>OLSSON, K</au><au>WESTERKAMP, V</au><au>WELTE, T</au><au>HOEPER, M. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2012-03-01</date><risdate>2012</risdate><volume>39</volume><issue>3</issue><spage>589</spage><epage>596</epage><pages>589-596</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>Current guidelines for the treatment of patients with idiopathic pulmonary arterial hypertension (IPAH) recommend basing therapeutic decision-making on haemodynamic, functional and biochemical variables. Most of these parameters have been evaluated as risk predictors at the time of diagnosis. The aim of the present study was to assess the prognostic impact of changes in these parameters after initiation of targeted therapy. A cohort of 109 patients with IPAH who had undergone haemodynamic, functional and biochemical assessments at baseline and 3-12 months after initiation of pulmonary arterial hypertension (PAH)-targeted therapy, were followed for a median 38 months in order to determine predictors of mortality at baseline and during the course of their disease. Within the observation period, 53 (48.6%) patients died and four (3.7%) underwent lung transplantation. Kaplan-Meier estimates for transplantation-free survival were 92%, 67%, and 51% at 1, 3, and 5 yrs, respectively. Among baseline variables, 6-min walk distance, right atrial pressure, cardiac index, mixed-venous oxygen saturation (S(v,O(2))) and N-terminal-pro brain natriuretic peptide (NT-proBNP) were independent predictors of survival. During follow-up, changes in World Health Organization functional class, cardiac index, S(v,O(2)) and NT-proBNP proved significant predictors of outcome. When assigned to prognostic groups, improvements as well as deteriorations in these parameters after initiation of PAH-targeted therapy had a strong impact on survival. Measurements obtained at follow-up had a higher predictive value than variables obtained at baseline. Changes in established predictors of outcome during the course of the disease provide important prognostic information in patients with IPAH.</abstract><cop>Leeds</cop><pub>Maney</pub><pmid>21885392</pmid><doi>10.1183/09031936.00092311</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0903-1936
ispartof The European respiratory journal, 2012-03, Vol.39 (3), p.589-596
issn 0903-1936
1399-3003
language eng
recordid cdi_proquest_miscellaneous_926153195
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Aged
Atrial Function, Right - physiology
Biological and medical sciences
Cohort Studies
Endothelin Receptor Antagonists
Epoprostenol - analogs & derivatives
Epoprostenol - therapeutic use
Exercise Test
Familial Primary Pulmonary Hypertension
Female
Follow-Up Studies
Humans
Hypertension, Pulmonary - drug therapy
Hypertension, Pulmonary - mortality
Hypertension, Pulmonary - surgery
Lung Transplantation
Male
Medical sciences
Middle Aged
Natriuretic Peptide, Brain - blood
Oxygen - blood
Peptide Fragments - blood
Phosphodiesterase 5 Inhibitors - therapeutic use
Pneumology
Prognosis
Prostaglandins - therapeutic use
Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases
Retrospective Studies
Severity of Illness Index
Treatment Outcome
title The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T23%3A55%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20prognostic%20impact%20of%20follow-up%20assessments%20in%20patients%20with%20idiopathic%20pulmonary%20arterial%20hypertension&rft.jtitle=The%20European%20respiratory%20journal&rft.au=NICKEL,%20N&rft.date=2012-03-01&rft.volume=39&rft.issue=3&rft.spage=589&rft.epage=596&rft.pages=589-596&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/09031936.00092311&rft_dat=%3Cproquest_cross%3E926153195%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=926153195&rft_id=info:pmid/21885392&rfr_iscdi=true